Immunocore Holdings (IMCR) Cash & Current Investments (2019 - 2026)

Immunocore Holdings (IMCR) has reported Cash & Current Investments for 8 consecutive years, with $844.9 million the latest figure, recorded in Q1 2026.

• Quarterly Cash & Current Investments rose 0.94% year-over-year to $844.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $844.9 million (up 0.94% YoY) and the FY2025 annual result came in at $864.2 million, up 5.34% from the prior year.
• Cash & Current Investments slipped to $844.9 million in Q1 2026 per IMCR's latest filing, from $864.2 million in the prior quarter.
• Over the last five years, Cash & Current Investments for IMCR reached as high as $901.3 million in Q3 2024 and fell as low as $262.0 million in Q2 2022.
• A 5-year average of $690.5 million and a median of $834.9 million in 2024 frame the typical range for Cash & Current Investments.
• Annual changes were most pronounced in 2024 — Cash & Current Investments soared 100.66% — and 2025, when it decreased 0.99%.
• Year by year, Cash & Current Investments stood at $390.0 million in 2022, then grew by 13.48% to $442.6 million in 2023, then surged by 85.34% to $820.4 million in 2024, then grew by 5.34% to $864.2 million in 2025, then decreased by 2.23% to $844.9 million in 2026.
• According to Business Quant data, Cash & Current Investments over the past three periods registered $844.9 million, $864.2 million, and $892.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.